Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Male and Female Volunteers

Stopped early · Phase 1 · Has a placebo group

Conditions studied: Metabolism and Nutrition Disorder, Obesity

In brief

This trial will be conducted in the United States of America (USA). The aim of the trial is to investigate whether the drug is safe, well tolerated and to investigate the efficacy of NNC 0070-0002-0182 for the treatment of obesity. The subjects will be treated with drug and placebo. This registration covers the phase 2 part of a combined phase 1/phase 2 trial (phase 1 part of trial conducted between November 2007 and April 2008).

Key facts

Study ID

NCT00665665

Run by

Novo Nordisk A/S

People needed

101

Starts

2007-11-01

Expected to finish

2008-10-01

Last updated by the study team

2016-12-23

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Body mass index (BMI) between 30.0-39.0 kg/m2 (obese)
• Females who consent to using double barrier method of contraception, are post-menopausal and older than 50 years, or have had total hysterectomy

You may not qualify if…

• Clinically significant diseases
• Blood pressure greater than 140/90 mmHg
• Evidence of depression
• Recent diet attempts, treatment with diet drugs (within 3 months)
• Liposuction or other surgery for weight loss within the last year
• Evidence of eating disorders (bulimia, binge eating)
• Restricted diets (Kosher, vegetarian)
• Smoker or history of drug or alcohol abuse
• Females of childbearing potential: positive pregnancy test

Where it is running

• Novo Nordisk Investigational Site — Evansville, Indiana, United States
• Novo Nordisk Investigational Site — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.